Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R2 | O00459 | 13/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988849 | 0.92 | PIK3R2 (0.38) | PIK3R2EGFRSIRT6MAPTMEN1 | |
| SCHEMBL19989075 | 0.89 | MAPT (0.40) | PIK3R2MAPTMEN1NPC1RAB9A | |
| SCHEMBL19989497 | 0.88 | PIK3R2 (0.41) | PIK3R2EGFRSIRT6MAPT | |
| SCHEMBL19989039 | 0.88 | PIK3R2 (0.39) | PIK3R2EGFRSIRT6MAPTFGFR3 | |
| SCHEMBL19989047 | 0.88 | PIK3R2 (0.41) | PIK3R2EGFRMAPT | |
| SCHEMBL19988972 | 0.87 | PIK3R2 (0.38) | PIK3R2SIRT6MAPTMEN1NPC1 | |
| SCHEMBL19988989 | 0.87 | PIK3R2 (0.41) | PIK3R2MAPTSMN1; SMN2 | |
| SCHEMBL19989216 | 0.87 | MAPT (0.39) | PIK3R2SIRT6MAPT | |
| SCHEMBL19989254 | 0.85 | PIK3R2 (0.42) | PIK3R2MAPT | |
| SCHEMBL19989069 | 0.85 | CLK2 (0.50) | PIK3R2EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057808-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | PIK3R2 18/4885EGFR 572/4885SIRT6 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.